Market News & Trends
Catalent Biologics Collaborates With PATH Malaria Vaccine Initiative to Create Antibodies for Malaria Vaccine R&D
Catalent Pharma Solutions recently announced it has signed an agreement with PATH, an international non-profit organization and a leader in global health innovation, to advance…
GW Pharmaceuticals Announces New Positive Phase III Data
GW Pharmaceuticals plc recently announced additional positive Epidiolex (cannabidiol or CBD) Phase III data in poster presentations at the 70th Annual Meeting of the American…
Aptar Pharma Nears Completion of Elastomer Component Capacity
Aptar Pharma, a leading provider of drug delivery systems, is nearing completion on its expansion at its Congers, NY, state-of-the-art manufacturing site. The new space…
Immune Design Provides Update From Two Discovery Platforms
Immune Design recently announced new data that highlight the broad product reach potential of both its Specific Antigen and Endogenous Antigen/Intratumoral immunization approaches. ZVexMulti offers…
G1 Therapeutics Announces Clinical Trial Collaboration With Genentech
G1 Therapeutics recently announced a clinical trial collaboration with Genentech, a member of the Roche Group. A Phase II clinical trial is expected to begin…
Amgen & Allergan Submit Biosimilar Marketing Authorization Application
Amgen and Allergan plc. recently announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215, a biosimilar…
Impel NeuroPharma Announces $36-Million Funding to Advance Novel Delivery Platform
Impel NeuroPharma, Inc. recently announced that it has closed a Series C funding round in an amount up to $36 million to advance its novel…
Catalent Becomes First CDMO to Join Pharmaceutical Supply Chain Initiative
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, recently announced that it had…
OncoMed Presents Initial First-in-Human Data
OncoMed Pharmaceuticals Inc. presented initial first-in-human data from its ongoing Phase I clinical trials of anti-DLL4/VEGF bispecific (OMP-305B83) and anti-RSPO3 (OMP-131R10) antibodies in two posters…
VBL Therapeutics Announces Overall Survival Data for VB-111 Monotherapy in Phase 2 Study
VBL Therapeutics recently announced top-line results from its exploratory Phase II study of VB-111 (ofranergene obadenovec) in patients with advanced, differentiated thyroid cancer. As previously…
Novan Announces Statistically Significant Phase II Clinical Trial Results
Novan, Inc. recently announced top-line results from the company’s Phase II clinical trial with SB206 for the treatment of genital warts caused by human papillomavirus,…
Cellular Biomedicine Group Approved to Commence Phase I Trial
Cellular Biomedicine Group Approved to Commence Phase I Trial Cellular Biomedicine Group Inc. (CBMG) recently announced the approval and commencement of patient enrollment in China…
Catalent Acquires Company to Expand Softgel Development & Manufacturing
Catalent, Inc. recently announced it has agreed to acquire Accucaps Industries Limited (Accucaps), the Canada-based developer and manufacturer of Over-the-Counter (OTC), high-potency, and conventional pharmaceutical…
Ablynx Achieves First Milestone From Novo Nordisk
Ablynx recently announced it has achieved an initial discovery milestone with a multi-specific Nanobody construct as part of its collaboration with Novo Nordisk, triggering a…
Stealth Biotherapeutics Announces Positive Phase II Clinical Trial Findings
Stealth BioTherapeutics recently presented results from the EVOLVE trial, which demonstrated that a single dose of elamipretide prior to renal artery angioplasty and stenting procedures…
TKL Research Agrees to Sell Clinical Trials Division
TKL Research, a dermatology specialty clinical research organization (CRO), recently announced it has signed an agreement to sell its Clinical Trials Division (CTD) to QuintilesIMS. Upon…
IP Assets of Biopharmaceuticals Delivery Specialists Brought to Market by Metis Partners
The IP assets of a recognized leader in the bioformulation and drug delivery industry, XstalBio Limited, which is behind CentuRecon – a patent-backed reconstitution technology…
Honeywell Launces New Research Chemicals Business to Optimize Product Partnerships With Researchers
Honeywell recently announced the launch of a new business, Honeywell Research Chemicals, that will now include several brands and solvent and inorganic chemical products that…
West Announces Expanded Contract Manufacturing Capabilities in Ireland
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the completion of a 60,000 square foot…
Mustang Bio Presents Clinical & Preclinical Data on MB-101 for Treatment of Glioblastoma
Mustang Bio, Inc., a Fortress Biotech company, recently announced that Phase I clinical data and preclinical data on its MB-101 [IL13Rα2-specific Chimeric Antigen Receptor–engineered CAR…
